Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled multicenter trial of Shaoling tablets for plaque psoriasis with blood stasis syndrome
CTR20221473Phase 2Active
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing Shaoling tablets with Placebo simulant (2 arms). Primary endpoint: Proportion of participants achieving PASI50. Started Sep 2023; status: active.
02
Drugs
Shaoling tablets
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20221473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221473.